Artículos del autor

solaci

Antiplatelet

TCT 2019 | EVOLVE Short DAPT: Only 3-month DATP in High Risk Bleeding

Courtesy of the SBHCI. This study used the thin strut everolimus eluting stent with ultrathin abluminal bioresorbable polymer...
solaci -
Antiplatelet

TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS

Courtesy of SBHCI. The safety and efficacy of antithrombotic and antiplatelet treatments in patients with atrial fibrillation...
solaci -
Coronary disease

TCT 2019 | IDEAL-LM: Bioabsorbable Polymer DES vs. Permanent Polymer DES for Left Main Stenosis

Courtesy of SBHCI. This study showed that using the everolimus eluting stent with bioabsorbable polymer Synergy followed by...
solaci -
Coronary disease

TCT 2019 | Onyx ONE: Durable Polymer vs. Polymer-Free Stent with Only One Month of Dual Antiplatelet Therapy

Courtesy of the SBHCI. This is the first randomized study comparing a durable-polymer drug-eluting stent (zotarolimus-eluting stent Onyx)...
solaci -
Antiplatelet

TCT 2019 | TWILIGHT: Minimal DAPT in High Bleeding Risk Patients

Courtesy of the SBHCI. Monotherapy with a P2Y12 inhibitor after a minimum period (3 months) of dual antiplatelet...
solaci -
International Congresses

TCT 2019

Discover the highlights of the 2019 TCT Congress, which took place between September 25th - 29th at...
solaci -
Structural heart disease

TAVR and Pacemakers, New Strategies

Courtesy of Dr. Carlos Fava. TAVR has been shown beneficial and is constantly being advanced onto lower risk...
solaci -
Events

Latin American Session at TCT 2019

Yesterday, Wednesday 25th September 2019, took place the session entitled The Best Intervention from Latin América at TCT...
solaci -